Pharmaceutical Investing Opiant Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results and Provides Corporate Update
Pharmaceutical Investing Daré Bioscience announces funding award to further the development of Ovaprene
Pharmaceutical Investing Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for Development of OPNT003
Pharmaceutical Investing Inovio and The Wistar Institute Receive More Than $4.6 Million in R&D Funding
MediciNova Announces MN-166 (ibudilast) Demonstrated a 26% Reduction in Confirmed Disability Progression
Athena Reports Results From 2024 Prospecting Program at Excelsior Springs, Outlines New Targets, and Expands Land Package
Juggernaut Further Increases Oversubscribed Financing to $10,329,735 Due to Strong Demand from Institutions and Accredited Investors -- Dr. Quinton Hennigh Technical Advisor
Cygnus Metals to Present at the Precious Metals & Critical Minerals Hybrid Investor Conference on May 22nd
Skyharbour and JV Partner Orano to Commence Extensive Summer 2025 Drilling Program at Preston Uranium Project
